Movatterモバイル変換

[0]ホーム
URL:

Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature Medicine
  • Historical Perspective
  • Published:

Vaccines: past, present and future

Nature Medicinevolume 11, pagesS5–S11 (2005)Cite this article

Abstract

The vaccines developed over the first two hundred years since Jenner's lifetime have accomplished striking reductions of infection and disease wherever applied. Pasteur's early approaches to vaccine development, attenuation and inactivation, are even now the two poles of vaccine technology. Today, purification of microbial elements, genetic engineering and improved knowledge of immune protection allow direct creation of attenuated mutants, expression of vaccine proteins in live vectors, purification and even synthesis of microbial antigens, and induction of a variety of immune responses through manipulation of DNA, RNA, proteins and polysaccharides. Both noninfectious and infectious diseases are now within the realm of vaccinology. The profusion of new vaccines enables new populations to be targeted for vaccination, and requires the development of routes of administration additional to injection. With all this come new problems in the production, regulation and distribution of vaccines.

This is a preview of subscription content,access via your institution

Access options

Access through your institution

Subscription info for Japanese customers

We have a dedicated website for our Japanese customers. Please go tonatureasia.com to subscribe to this journal.

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

￥ 4,980

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Pseudo-particles of human papillomavirus type 16 formed by self-assembly of the L1 viral protein.
Figure 2: Scanning electron photomicrograph of a microprojection array used to deliver antigen to the skin.

Similar content being viewed by others

References

  1. Fenner, F., Henderson, D.A., Arita, I., Jezek, Z. & Ladnyi, I.D. Early efforts at control: variolation, vaccination, and isolation and quarantine. inHistory of International Public Health, No. 6 (eds Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., Ladnyi, I.D.) 245–276 (World Health Organization, Geneva, 1988).

    Google Scholar 

  2. Plotkin, S.L. & Plotkin, S.A. A short history of vaccination. inVaccines 4th edn (eds. Plotkin, S.A. & Orenstein, W.A.) 1–15 (W.B. Saunders, Philadelphia, 2004).

    Google Scholar 

  3. Fenn, E.A. Pox Americana: The Great Smallpox Epidemic of 1775-82. 1 (Hill and Wang, New York, 2001).

  4. Pasteur, L. De l'attenuation du virus du cholera des poules.C. R. Acad. Sci. Paris91, 673–680 (1880).

    Google Scholar 

  5. Pasteur, L., Chamberland, C.-E. : Sur la vaccination charbonneuse.C. R. Acad. Sci. Paris92, 1378–1383 (1881).

    Google Scholar 

  6. Calmette, A., Guerin, C., Breton, M. Contribution a l'etude de la tuberculose experimental du cobaye (infection et essais de vaccination par la voie digestive).Ann. Inst. Pasteur Paris21, 401–416 (1907).

    Google Scholar 

  7. Theiler, M., Smith, H.H. The use of yellow fever virus byin vitro cultivation for human immunization.J. Exp. Med.65, 787–800 (1937).

    Article CAS PubMed PubMed Central  Google Scholar 

  8. Weller, T.H. Cultivation of poliomyelitis virus in cultures of human foreskin and embryonic tissues.Proc. Soc. Exp. Biol. Med.72, 153–155 (1949).

    Article CAS PubMed  Google Scholar 

  9. Kilbourne, E.D. & Murphy, J.S. Genetic studies of influenza viruses. I. Viral morphology and growth capacity as exchangeable genetic traits. Rapid in ovo adaptation of early passage Asian strain isolates by combination with PR8.J. Exp. Med.111, 387–406 (1960).

    Article CAS PubMed PubMed Central  Google Scholar 

  10. Clark, H.F., Offit, P., Glass, R.I., Ward, R.L. Rotavirus vaccines. inVaccines 4th edn. (eds. Plotkin, S.A. & Orenstein, W.A.) 1327–1345 (Elsevier, Philadelphia, 2004).

    Google Scholar 

  11. Bernstein, D.I. et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12.Vaccine16, 381–387 (1998).

    Article CAS PubMed  Google Scholar 

  12. Salmon, D.E. & Smith, T. On a new method of producing immunity from infectious diseases.Am. Vet. Rev.10, 63–69 (1886).

    Google Scholar 

  13. Ramon, G. Sur le pouvoir floculant et sur les proprietes immunisantes d'une toxine diphterique rendu anatoxique (anatosine).C. R. Acad. Sci. Paris177, 1338–1340 (1923).

    Google Scholar 

  14. Ramon, G. & Zeller, C. De la valeur antigenique de l'anatoxine tetanique chez l'homme.C. R. Acad. Sci. Paris182, 245–247 (1926).

    Google Scholar 

  15. Schneerson, R., Barrera, O., Sutton, A. & Robbins, J.B. Preparation, characterization, and immunogenicity ofHaemophilus influenzae type b polysaccharide-protein conjugates.J. Exp. Med.152, 361–376 (1980).

    Article CAS PubMed  Google Scholar 

  16. Moingeon, P. Cancer vaccines.Vaccine9, 1305–1326 (2001).

    Article  Google Scholar 

  17. McAleer, W.J., Buynak, E.B., Maigetter, R.Z., Wampler, D.E., Miller, W.J. & Hilleman M.R. Human hepatitis B vaccine from recombinant yeast.Nature307, 178–180 (1984).

    Article CAS PubMed  Google Scholar 

  18. Szmuness, W., Stevens, C.E., Zang, E.A., Harley, E.J. & Kellner, A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.Hepatology1, 377–385 (1981).

    Article CAS PubMed  Google Scholar 

  19. Fikrig, E., Barthold, S.W., Kantor, F.S. & Flavell, R.A. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA.Science250, 553–556 (1990).

    Article CAS PubMed  Google Scholar 

  20. Spaete, R.R. A recombinant subunit vaccine approach to HCMV vaccine development.Transplant. Proc.23, 90–96 (1991).

    CAS PubMed  Google Scholar 

  21. Pizza, M. et al. Mutants of pertussis toxin suitable for vaccine development.Science246, 497–500 (1989).

    Article CAS PubMed  Google Scholar 

  22. Durbin, A.P. & Karron, R.A. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.Clin. Infect. Dis.37, 1668–1677 (2003).

    Article CAS PubMed  Google Scholar 

  23. Guirakhoo, F. et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.J. Virol.78, 4761–4775 (2004).

    Article CAS PubMed PubMed Central  Google Scholar 

  24. Plotkin, S.A. Six revolutions in vaccinology.Pediatr. Infect. Dis. J.24, 1–9 (2005)

    Article PubMed  Google Scholar 

  25. Excler, J.L. & Plotkin, S. The prime-boost concept applied to HIV preventive vaccines.AIDS11 Suppl A, S127–S137 (1997).

    PubMed  Google Scholar 

  26. Amara, R.R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.Vaccine20, 1949–1955 (2002).

    Article CAS PubMed  Google Scholar 

  27. Moore, A.C. & Hill, A.V. Progress in DNA-based heterologous prime-boost immunization strategies for malaria.Immunol. Rev.199, 126–143 (2004).

    Article CAS PubMed  Google Scholar 

  28. Rayner, J.O., Dryga, S.A. & Kamrud, K.I. Alphavirus vectors and vaccination.Rev. Med. Virol.12, 279–296 (2002).

    Article CAS PubMed  Google Scholar 

  29. Schiller, J.T. & Davies, P. Delivering on the promise: HPV vaccines and cervical cancer.Nat. Rev. Microbiol.2, 343–347 (2004).

    Article CAS PubMed  Google Scholar 

  30. Koutsky, L.A. et al. A controlled trial of a human papillomavirus type 16 vaccine.N. Engl. J. Med.347, 1645–1651 (2002).

    Article CAS PubMed  Google Scholar 

  31. Huang, Y., Yang, Z.-Y., Kong, W.P. & Nabel, G.J. Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: implications for assembly and vaccine production.J. Virol.78, 12557–12565 (2004).

    Article CAS PubMed PubMed Central  Google Scholar 

  32. Ulmer, J.B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein.Science259, 1745–1749 (1993).

    Article CAS PubMed  Google Scholar 

  33. Robinson, H.L. Nucleic acid vaccines: an overview.Vaccine15, 785–787 (1997).

    Article CAS PubMed  Google Scholar 

  34. Reddy, S.T. & Ertl, H.C. The potential use of DNA vaccines for neonatal immunization.Curr. Opin. Mol. Ther.1, 22–29 (1999).

    CAS PubMed  Google Scholar 

  35. Neumann, G. et al. Generation of influenza A viruses entirely from cloned cDNAs.Proc. Natl. Acad. Sci. USA96, 9345–9350 (1999).

    Article CAS PubMed PubMed Central  Google Scholar 

  36. Palese, P. & Garcia, S.A. Influenza vaccines: present and future.J. Clin. Invest.110, 9–13 (2002).

    Article CAS PubMed PubMed Central  Google Scholar 

  37. Wood, J.M. & Robertson, J.S. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza.Nat. Rev. Microbiol.2, 842–847 (2004).

    Article CAS PubMed  Google Scholar 

  38. Mora, M., Veggi, D., Santini, L., Pizza, M. & Rappuoli, R. Reverse vaccinology.Drug Discov. Today8, 459–464 (2003).

    Article CAS PubMed  Google Scholar 

  39. Dhiman, N., Bonilla, R., O'Kane, D.J. & Poland, G.A. Gene expression microarrays: a 21st century tool for directed vaccine design.Vaccine20, 22–30 (2001).

    Article CAS PubMed  Google Scholar 

  40. Serruto, D., Adu-Bobie, J., Capecchi, B., Rappuoli, R., Pizza, M. & Masignani, V. Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens.J. Biotechnol.113, 15–32 (2004).

    Article CAS PubMed  Google Scholar 

  41. Lambert, P-H. Companion paper.Nat. Med.11 Suppl 1, S54–S62 (2005).

    Article CAS PubMed  Google Scholar 

  42. Plotkin, S.A. Immunologic correlates of protection induced by vaccination.Pediatr. Infect. Dis. J.20, 63–75 (2001).

    Article CAS PubMed  Google Scholar 

  43. BenMohamed, L., Wechsler, S.L. & Nesburn, A.B. Lipopeptide vaccines—yesterday, today, and tomorrow.Lancet Infect. Dis.2, 425–431 (2002).

    Article CAS PubMed  Google Scholar 

  44. Moingeon, P., Haensler, J. & Lindberg, A. Towards the rational design of Th1 adjuvants.Vaccine19, 4363–4372 (2001).

    Article CAS PubMed  Google Scholar 

  45. Autran, B., Molet, L. & Lederman, M.M. Host defenses against viral infection. inPractical Guidelines in Antiviral Therapy (eds. Boucher, C.A. & Galasso, G.A) 65–94 (Elsevier, Philadelphia, 2002).

    Chapter  Google Scholar 

  46. O'Garra, A. & Vieira, P. Regulatory T cells and mechanisms of immune system control.Nat. Med.10, 801–805 (2004).

    Article CAS PubMed  Google Scholar 

  47. Decker, M.D., Edwards, K.M. & Bogaerts, H.H. Combination vaccines. inVaccine 4th edn. (eds. Plotkin, S.A. & Orenstein, W.A.) 825–861 (Elsevier, Philadelphia, 2004)

    Google Scholar 

  48. Klinman, D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides.Nat. Rev. Immunol.4, 249–258 (2004).

    Article CAS PubMed  Google Scholar 

  49. Sela, M. & Hilleman, M.R. Therapeutic vaccines: realities of today and hopes for tomorrow.Proc. Natl. Acad. Sci. USA101 Suppl 2, 14559 (2004).

    Article CAS PubMed PubMed Central  Google Scholar 

  50. Vandepapeliere, P. Therapeutic vaccination against chronic viral infections.Lancet Infect. Dis.2, 353–367 (2002).

    Article PubMed  Google Scholar 

  51. Hallez, S. et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.Cancer Immunol. Immunother.53, 642–650 (2004).

    Article CAS PubMed  Google Scholar 

  52. Markowitz, M. et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.J. Infect. Dis.186, 634–643 (2002).

    Article CAS PubMed  Google Scholar 

  53. Buckner, C. et al. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.Virology320, 167–180 (2004).

    Article CAS PubMed  Google Scholar 

  54. Belshe, R.B. et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.J. Pediatr.136, 168–175 (2000).

    Article CAS PubMed  Google Scholar 

  55. Sepulveda-Amor, J. et al. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children.Vaccine20, 2790–2795 (2002).

    Article PubMed  Google Scholar 

  56. Jones, T. et al. A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.Vaccine21, 3706–3712 (2003).

    Article CAS PubMed  Google Scholar 

  57. Tacket, C.O. Garden-variety vaccines: antigens derived from transgenic plants.Expert Rev. Vaccines3, 529–531 (2004).

    Article CAS PubMed  Google Scholar 

  58. Webster, D.E. et al. Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine.J. Virol.76, 7910–7912 (2002).

    Article CAS PubMed PubMed Central  Google Scholar 

  59. Stevceva, L. & Strober, W. Mucosal HIV vaccines: where are we now?Curr. HIV Res.2, 1–10 (2004).

    Article CAS PubMed  Google Scholar 

  60. Hammond, S.A., Walwender, D., Alving, C.R. & Glenn, G.M. Transcutaneous immunization: T cell responses and boosting of existing immunity.Vaccine19, 2701–2707 (2001).

    Article CAS PubMed  Google Scholar 

  61. Glenn, G.M., Kenney, R.T., Ellingsworth, L.R., Frech, S.A., Hammond, S.A. & Zoeteweij, J.P. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin.Expert Rev. Vaccines2, 253–267 (2003).

    Article CAS PubMed  Google Scholar 

  62. Matyas, G.R., Friedlander, A.M., Glenn, G.M., Little, S., Yu, J. & Alving, C.R. Needle-free skin patch vaccination method for anthrax.Infect. Immun.72, 1181–1183 (2004).

    Article CAS PubMed PubMed Central  Google Scholar 

  63. Chen, D. et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine.Vaccine21, 2830–2836 (2003).

    Article CAS PubMed  Google Scholar 

  64. Mikszta, J.A., Alarcon, J.B., Brittingham, J.M., Sutter, D.E., Pettis, R.J. & Harvey, N.G. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery.Nat. Med.8, 415–419 (2002).

    Article CAS PubMed  Google Scholar 

  65. Finn, O.J. Cancer vaccines: between the idea and the reality.Nat. Rev. Immunol.3, 630–641 (2003).

    Article CAS PubMed  Google Scholar 

  66. Lewis, J.J. Therapeutic cancer vaccines: using unique antigens.Proc. Natl. Acad. Sci. USA101 Suppl 2, 14653–14656 (2004).

    Article CAS PubMed PubMed Central  Google Scholar 

  67. Hohlfeld, R. & Wekerle, H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.Proc. Natl. Acad. Sci. USA101Suppl 2, 14599–14606 (2004).

    Article CAS PubMed PubMed Central  Google Scholar 

  68. Petrovsky, N., Silva, D. & Schatz, D.A. Vaccine therapies for the prevention of type 1 diabetes mellitus.Paediatr. Drugs5, 575–582 (2003).

    Article PubMed  Google Scholar 

  69. Niederberger, V. et al. Vaccination with genetically engineered allergens prevents progression of allergic disease.Proc. Natl. Acad. Sci. USA101 Suppl 2, 14677–14682 (2004).

    Article CAS PubMed PubMed Central  Google Scholar 

  70. Singh, M., Das, S.K., Suri, S., Singh, O. & Talwar, G.P. Regain of fertility and normality of progeny born during below protective threshold antibody titers in women immunized with the HSD-hCG vaccine.Am. J. Reprod. Immunol.39, 395–398 (1998).

    Article CAS PubMed  Google Scholar 

  71. Mettens, P. & Monteyne, P. Life-style vaccines.Br. Med. Bull.62, 175–186 (2002).

    Article PubMed  Google Scholar 

  72. Gelinas, D.S., DaSilva, K., Fenili, D., George-Hyslop, P. & McLaurin, J. Immunotherapy for Alzheimer's disease.Proc. Natl. Acad. Sci. USA101 Suppl 2, 14657–14662 (2004).

    Article CAS PubMed PubMed Central  Google Scholar 

  73. Kantak, K.M., Collins, S.L., Lipman, E.G., Bond, J., Giovanoni, K. & Fox, B.S. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model.Psychopharmacology (Berl.)148, 251–262 (2000).

    Article CAS  Google Scholar 

  74. Forsyth, K.D., et al. New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative.Clin. Infect. Dis.39, 1802–1809 (2004).

    Article PubMed  Google Scholar 

  75. Stanberry, L.R. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.Herpes11 Suppl 3, 161A–169A (2004).

    Google Scholar 

  76. Arvin, A.M., Fast, P., Myers, M., Plotkin, S. & Rabinovich, R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee.Clin. Infect. Dis.39, 233–239 (2004).

    Article PubMed  Google Scholar 

  77. Levin, M.J. et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine.J. Infect. Dis.188, 1336–1344 (2003).

    Article PubMed  Google Scholar 

  78. Baker, C.J., Paoletti, L.C., Rench, M.A., Guttormsen, H.K., Edwards, M.S. & Kasper, D.L. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.J. Infect. Dis.189, 1103–1112 (2004).

    Article CAS PubMed  Google Scholar 

  79. Munoz, F.M., Piedra, P.A. & Glezen, W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women.Vaccine21, 3465–3467 (2003).

    Article CAS PubMed  Google Scholar 

  80. Fattom, A.I., Horwith, G., Fuller, S., Propst, M. & Naso, R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials.Vaccine22, 880–887 (2004).

    Article CAS PubMed  Google Scholar 

  81. Hassani, M., Patel, M.C. & Pirofski, L.A. Vaccines for the prevention of diseases caused by potential bioweapons.Clin. Immunol.111, 1–15 (2004).

    Article CAS PubMed  Google Scholar 

  82. McCurdy, L.H., Larkin, B.D., Martin, J.E. & Graham, B.S. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.Clin. Infect. Dis.38, 1749–1753 (2004).

    Article PubMed  Google Scholar 

  83. WHO collaborative study group: The relationship between persisting spinal paralysis and poliomyelitis vaccine—results of a ten-year enquiry.Bull WHO60, 231–242 (1982).

  84. Hoft, D.F. et al. Clinical reactogenicity of intradermal bacille Calmette-Guerin vaccination.Clin. Infect. Dis.28, 785–790 (1999).

    Article CAS PubMed  Google Scholar 

  85. Horwitz, M.A. & Harth, G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis.Infect. Immun.71, 1672–1679 (2003).

    Article CAS PubMed PubMed Central  Google Scholar 

  86. Morse, S.S. The viruses of the future? Emerging viruses and evolution. inThe Evolutionary Biology of Viruses (ed Morse, S.S.) 325–335 (Raven Press, New York, 1994).

    Google Scholar 

  87. Matriano, J.A. et al. Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization.Pharm. Res.19, 63–70 (2002).

    Article CAS PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sanofi Pasteur and the University of Pennsylvania, 4650 Wismer Road, Doylestown, 18901, Pennsylvania, USA

    Stanley A Plotkin

Authors
  1. Stanley A Plotkin

Corresponding author

Correspondence toStanley A Plotkin.

Ethics declarations

Competing interests

Stanley A. Plotkin is an employee of Sanofi Pasteur.

Rights and permissions

This article is cited by

Access through your institution
Buy or subscribe

Associated content

Supplement

Vaccines

Advertisement

Search

Advanced search

Quick links

Nature Briefing

Sign up for theNature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox.Sign up for Nature Briefing
[8]ページ先頭
©2009-2026 Movatter.jp